Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

Article ID	Journal	Published Year	Pages	File Type
8713095	Journal of Allergy and Clinical Immunology	2018	19 Pages	PDF

Keywords

CRISPR pStat SOCS GOF CCD ADCC CMC DBD Janus kinase natural killer Ruxolitinib STAT antibody-dependent cellular cytotoxicity Gain of function clustered regularly interspaced short palindromic repeats Coiled-coil domain DNA-Binding Domain suppressor of cytokine signaling Signal transducer and activator of transcription wild-type Perforin JAK chronic mucocutaneous candidiasis

Related Topics

Life Sciences Immunology and Microbiology Immunology

Preview

Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations

Authors

Alexander PhD, Emily M. PhD, Ofer MD, Christa S. MD, Alexandra F. MD, Sergio MD, PhD, Jennifer W. MD, Troy MD, PhD, Matthew C. MD, Edith MD, Charlotte MD, PhD, Ivan K. MD, Alexandre F. PhD, Imelda C. MD, Nicholas L. DO, Steven M. MD, Jordan S. MD, PhD,